Lpath Granted Key European and U.S. Patents Related to Anti-Cancer Drug Program, ASONEP

Lpath Granted Key European and U.S. Patents Related to Anti-Cancer Drug 
Program, ASONEP 
Patents Provide Coverage for Lpath's Anti-S1P Antibody in the
Treatment of a Wide Variety of Hyperproliferative Disorders,
Including Cancer 
SAN DIEGO, CA -- (Marketwire) -- 03/22/13 --  Lpath, Inc. (NASDAQ:
LPTN), the industry leader in bioactive lipid-targeted therapeutics,
received official notification from the European Patent Office (EPO)
and the U.S. Patent and Trademark Office (USPTO) that the company has
been issued three key patents.  
The patents cover methods of detecting sphingolipid levels, as well
as covering monoclonal antibodies, including ASONEP(TM) and
iSONEP(TM), that bind to and neutralize sphingosine-1-phosphate
(S1P). S1P is a bioactive lipid that has been validated as a target
in multiple disease states. 
The newly issued U.S. patent, No. 8,361,465, claims ASONEP and
fragments of ASONEP for the treatment of cancer in combination with
chemotherapeutic agents and optionally surgery or radiation therapy.  
European patent No. EP 1 812 797 claims anti-S1P antibodies for use
in treating a wide range of hyperproliferative disorders, including
cancer, tumor angiogenesis, age-related macular degeneration (AMD),
cardiac failure, inflammation, and scarring. Claims are also granted
in Europe for anti-S1P antibodies in combination with other
treatments.  
A third patent, EP 2 027 142, was also granted in Europe. It has
claims to reagents and methods useful in diagnostic tests for
detecting and measuring certain sphingolipid levels in clinical
tissue or bodily fluid samples. Many scientific publications have
suggested that S1P is a tumorigenic and angiogenic bioactive lipid
that cancer cells use to escape therapy. In collaboration with Dr.
Rupal Bhatt of Beth Israel Deaconess Medical Center, Lpath has
demonstrated that levels of S1P are upregulated in blood of patients
with renal cell carcinoma (RCC). Moreover, Dr. Bhatt has demonstrated
efficacy of Lpath's anti-S1P antibodies in treating mice with human
RCC tumors.  
"In addition to previously issued Lpath patents, these key patents
provide additional exclusivity for ASONEP in the U.S. for cancer, as
well as exclusivity for all anti-S1P antibodies in Europe for wet
AMD," said Roger Sabbadini
, Lpath's vice president, founder, and an
inventor of the granted patents. "Lpath will continue to pursue other
disease indications and corresponding intellectual property in the
future."  
ASONEP(TM) and iSONEP(TM) are different formulations of sonepcizumab,
a first-in-class therapeutic antibody against S1P developed using
Lpath's ImmuneY2(TM) drug-discovery engine. Antibodies developed via
this discovery engine are designed to target bioactive signaling
lipids, such as S1P, that are involved in cancer, AMD, inflammatory
and auto-immune disorders, and many other diseases. 
Lpath has initiated a Phase 2 clinical trial for iSONEP, called
Nexus, which is evaluating the anti-S1P antibody's safety and
efficacy in wet-AMD patients. Lpath entered into an agreement with
Pfizer (NYSE: PFE) in 2010 that provides Pfizer an exclusive option
for a worldwide license to develop and commercialize iSONEP.  
In addition, Lpath is independently conducting an ASONEP Phase 2
trial in RCC patients, which is currently open for enrollment.  
About Lpath's Patent Portfolio
 Over the course of the company's
development, Lpath has achieved a broad and deep intellectual
property position in the bioactive-lipid area. The company's
comprehensive patent portfolio now includes 35 issued patents
(including ten international) and 112 patent applications (including
85 international). These patents primarily relate to the use of
reagents and methods designed to interfere with the actions of
bioactive lipids involved in human disease. Lpath's intellectual
property portfolio includes coverage of compositions of matter that
specifically bind to sphingolipids and sphingolipid metabolites.
These compositions, including antibodies, could be used in the
diagnosis and treatment of various diseases and disorders, including
cardiovascular and cerebrovascular disease, cancer, inflammation,
autoimmune disorders, ocular disease, and angiogenesis.  
Lpath has also obtained issued patent claims on sphingolipid targets
(e.g., receptors and signaling sphingolipids) and methods for using
such targets in drug-discovery screening efforts.  
The company believes that its patent portfolio provides broad and
commercially significant coverage of antibodies, receptors, enzymes,
and other moieties that bind to a lysolipid (or a sphingolipid
metabolite) for diagnostic, therapeutic, and screening purposes. 
About Lpath
 San Diego-based Lpath, Inc., a therapeutic antibody
company, is the category leader in lipid-targeted therapeutics. The
company's ImmuneY2(TM) drug-discovery engine has the unique ability
to generate monoclonal antibodies that bind to and inhibit bioactive
lipids that contribute to disease. The company is developing three
drug candidates: iSONEP(TM) is being studied in a Phase 2 trial in
wet AMD patients; ASONEP(TM) is being studied in a Phase 2 trial in
renal cell carcinoma patients; and Lpathomab is a preclinical drug
candidate that holds promise in pain, neurotrauma, and other
diseases. For more information, visit www.Lpath.com. 
About Forward-Looking Statements
 The Company cautions you that the
statements included in this press release that are not a description
of historical facts are forward-looking statements. These include
statements regarding: the protection against competition afforded by
issued patents; the eventual commercial viability of the Company's
drug programs; and the Company's ability to complete additional
discovery and development activities for drug candidates utilizing
its proprietary ImmuneY2 drug discovery process. Actual results may
differ materially from those set forth in this press release due to
the risks and uncertainties inherent in the Company's business,
including, without limitation: the outcome of the final analyses of
the data from the Phase 1 clinical trial may vary from the Company's
initial conclusions; the results of any future clinical trials for
iSONEP or ASONEP may not be favorable and the Company may never
receive regulatory approval for iSONEP or ASONEP or any of its drug
candidates; and the Company's may not be able to secure the funds
necessary to support its clinical trial and product development
plans. More detailed information about the Company and the risk
factors that may affect t
he realization of forward-looking statements
is set forth in the Company's filings with the Securities and
Exchange Commission, including its Annual Report on Form 10-K and its
Quarterly Reports on Form 10-Q filed with the SEC. Such documents may
be read free of charge on the SEC's web site at www.sec.gov. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. All
forward-looking statements are qualified in their entirety by this
cautionary statement and the Company undertakes no obligation to
revise or update this press release to reflect events or
circumstances after the date hereof. This caution is made under the
safe harbor provisions of Section 21E of the Private Securities
Litigation Reform Act of 1995. 
Lpath, Inc.
Scott R. Pancoast
President & CEO
Tel: (858) 926-3200 
spancoast@Lpath.com 
Lpath Investor Relations
Liolios Group, Inc.
Tel: (949) 574-3860
lptn@liolios.com
Ron Both: ron@liolios.com 
Geoffrey Plank: geoffrey@liolios.com